WOOJUNG BIO Inc Total Assets
WOOJUNG BIO Inc total assets. Based on the latest financial reports, WOOJUNG BIO Inc (215380) holds total assets worth ₩103.30 Billion KRW (≈ $70.00 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 215380 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of WOOJUNG BIO Inc (2016–2025)
Total assets of WOOJUNG BIO Inc from 2016 to 2025. This chart illustrates how WOOJUNG BIO Inc's total assets have evolved over time, based on quarterly financial data. See 215380 live share price for real-time trading data and today's change.
WOOJUNG BIO Inc - Asset Composition Analysis
WOOJUNG BIO Inc Total Assets Breakdown (December 2025)
WOOJUNG BIO Inc total assets breakdown as of December 2025. WOOJUNG BIO Inc's total assets of ₩103.30 Billion consist of 19.7% current assets and 80.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 4.4% |
| Accounts Receivable | ₩3.74 Billion | 4.3% |
| Inventory | ₩7.97 Billion | 9.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩885.43 Million | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how WOOJUNG BIO Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 215380 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: WOOJUNG BIO Inc's current assets represent 19.7% of total assets in 2025, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 4.4% of total assets in 2025, down from 21.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 9.2% of total assets.
WOOJUNG BIO Inc Competitors by Total Assets
Key competitors of WOOJUNG BIO Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
WOOJUNG BIO Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.55 | 0.56 | 0.78 |
| Quick Ratio | 0.39 | 0.34 | 0.67 |
| Cash Ratio | 0.00 | 0.00 | 0.01 |
| Working Capital | ₩-29.22 Billion | ₩-14.18 Billion | ₩-7.23 Billion |
WOOJUNG BIO Inc - Advanced Valuation Insights
This section examines the relationship between WOOJUNG BIO Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.3% |
| Total Assets | ₩86.80 Billion |
| Market Capitalization | $21.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values WOOJUNG BIO Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: WOOJUNG BIO Inc's assets decreased by 8.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for WOOJUNG BIO Inc (2016–2025)
The table below shows the annual total assets of WOOJUNG BIO Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩86.80 Billion ≈ $58.82 Million |
-8.35% |
| 2024-12-31 | ₩94.70 Billion ≈ $64.18 Million |
-3.70% |
| 2023-12-31 | ₩98.33 Billion ≈ $66.64 Million |
+3.51% |
| 2022-12-31 | ₩94.99 Billion ≈ $64.38 Million |
-5.14% |
| 2021-12-31 | ₩100.14 Billion ≈ $67.86 Million |
+43.43% |
| 2020-12-31 | ₩69.82 Billion ≈ $47.31 Million |
+21.14% |
| 2019-12-31 | ₩57.63 Billion ≈ $39.06 Million |
+28.61% |
| 2018-12-31 | ₩44.81 Billion ≈ $30.37 Million |
+42.72% |
| 2017-12-31 | ₩31.40 Billion ≈ $21.28 Million |
+161.65% |
| 2016-12-31 | ₩12.00 Billion ≈ $8.13 Million |
-- |
About WOOJUNG BIO Inc
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and e… Read more